f-star raises € 15M in a New Financing led by SR One
April 13th, 2011

f-star and Boehringer Ingelheim to collaborate in discovery and development of therapeutic antibodies
November 22nd, 2010

f-star raises € 8M in an Extended Series A Financing co-led by MP Healthcare Venture Management and Merck Serono Ventures
January 6th, 2010

Kevin FitzGerald joins f-star as new CEO starting from May 1st, 2009
April 17th, 2009

f-star buys back royalties, TVM Capital invests
March 28th, 2008

f-star opens research site in Cambridge, UK
March 12th, 2008

f-star establishes Scientific Advisory Board
December 12th, 2007

f-star increases Series A to € 9M
November 28th, 2007

f-star raises € 6M in Series A financing
September 10th, 2007

€ 1.5M seed financing from Atlas Venture
January 8th, 2007

f-star is a next generation antibody company developing improved therapeutic antibodies and antibody fragments based on its unique Modular Antibody Technology.

Modular Antibody Technology allows the introduction of additional binding sites into antibodies and antibody fragments by engineering the non-CDR loops of constant or variable domains. Using Modular Antibody Technology, small sized antibody fragments with full antibody functionality (Fcab™) or full length antibodies with additional functionality (mAb²) can be created.

Founded in 2006, the Company currently employs more than twenty highly qualified people at its research sites in Vienna, Austria and Cambridge, UK. In its Advisory Board, the Company is supported by pioneers in the research and development of monoclonal antibodies including Sir Ravinder Maini, Prof. Anthony Rees and Sir Gregory Winter.

f-star’s management team has many years of experience in the biotech and pharmaceutical industry, covering antibody engineering, pharmaceutical development, intellectual property, business development and finance.

f-star enjoys the strong financial support from a world-class group of life science investors including Aescap Venture, Atlas Venture, Novo A/S and TVM Capital.